CAS: 192725-17-0; (S)-N-((2S,4S,5S)-5-(2-(2,6-Dimethylphenoxy)Acetamido)-4-Hydroxy-1,6-Diphenylhexan-2-yl)-3-Methyl-2-(2-Oxotetrahydropyrimidin-1(2H)-yl)Butanamide

上下游产品

CAS号192725-49-8 N-[(1S,2S,4S)-4... | CAS号192725-50-1 (2S)-(1-四氢嘧啶-2-... | CAS号192800-77-4 (S) 3-METHYL-2-... | CAS号72-18-4 l-缬氨酸 | CAS号126147-70-4 (S)-3-甲基-2-((苯氧... | CAS号144163-85-9 [(1S,3S,4S)-4-氨... | CAS号156732-15-9 2S,3S,5S-2,2-二苄... | CAS号162849-93-6 (2S,3S,5S)-2-(N...

L-缬氨酸置于5%-Palladium/activated Carbon,氨,氢气,甲酸铵,碳酸氢钠,N,N'-羰基二咪唑,Potassium Hydroxide,Sodium Hydroxide体系中,用 甲醇,水,乙酸乙酯 用作溶剂,化学反应 20.5H,反应生成洛匹那韦
参考文献:Synthesis And Characterization Of Novel Analogues Of Lopinavir
标题:Synthesis And Characterization Of Novel Analogues Of Lopinavir
摘要:这项工作描述了四种洛匹那韦新颖类似物的鉴定,起源,合成,表征和控制,即洛匹那韦的亮氨酸类似物,异亮氨酸类似物,甲基类似物和二羟基类似物.
Doi:10.14233/ajchem.2021.22954

专利信息

专利号:US-8987493-B2
优先权日:2010-05-20
标题 :Process for synthesis of silane dipeptide analogs
发明人：SIEBURTH SCOTT MCNEILL; BO YINGJIAN
权利人:SIEBURTH SCOTT MCNEILL; BO YINGJIAN; Temple University—Of the Commonwealth System of Higher Education
摘要:The invention provides a method of preparing silane dipeptide analogs, comprising the steps of treating a solution of a substituted 1,2-oxasilolane with lithium metal to form a solution of the dilithium salt of a substituted 3-hydroxypropylsilanol, and reacting the solution of the dilithium salt of the substituted 3-hydroxypropylsilanol with a substituted enamine.

专利号:US-2010261876-A1
优先权日:2007-09-25
标 题:Novel methods of synthesis for therapeutic antiviral peptides
发明人：BRAY BRIAN L; JOHNSTON BARBARA E; SCHNEIDER STEPHEN E; TVERMOES NICOLAI A; ZHANG HUYI; FRIEDRICH PAUL E
权利人:BRAY BRIAN L; JOHNSTON BARBARA E; SCHNEIDER STEPHEN E; TVERMOES NICOLAI A; ZHANG HUYI; FRIEDRICH PAUL E
摘要:Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.

专利号:US-2025206743-A1
优先权日:2022-03-25
标 题:Tyk2 inhibitor synthesis and intermediates thereof
发明人：MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
权利人:TAKEDA PHARMACEUTICALS CO
摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

专利号:US-11845970-B2
优先权日:2016-01-15
标 题:Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins
发明人：WANG LAI-XI; YANG QIANG; LI TIEZHENG; TONG XIN
权利人:UNIV MARYLAND
摘要:The present invention provides for recombinant Endo-S2 mutants (named Endo-S2 glycosynthases) that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. As such, the present invention allows for the synthesis and remodeling of therapeutic antibodies thereby providing for certain biological activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and/or ability to deliver a therapeutic agent.

专利号:US-2016185745-A1
优先权日:2013-08-07
标题:Analogs of vinaxanthone and xanthofulvin, methods of synthesis, and methods of treatments thereof
发明人：SIEGEL DIONICIO; CHIN MATTHEW; ELIASEN ANDERS; AXELROD ABRAM
权利人:UNIV TEXAS
摘要:The present invention relates generally to methods of synthesis of vinaxanthone and xanthofulvin, novel analogs, and methods of use thereof.

专利号:US-11649285-B2
优先权日:2016-08-03
标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
发明人：KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN
权利人:BIO TECHNE CORP
摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.